Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
Busulfan Based Versus Total Body Irradiation Based for Adults Acute B Lymphoblastic Leukemia in CR2: An Multicenter, Non-Inferiority Study
This is an multicenter, non-inferiority randomized controlled trial. Adult patients (14-65 years) with acute lymphoblastic leukemia in second complete remission (CR2) scheduled for allogeneic hematopoietic stem-cell transplantation (allo-HSCT) will be randomized 1:1 to receive either busulfan-based chemotherapy-only conditioning (experimental arm) or total-body-irradiation (TBI)-based conditioning (active comparator arm). The primary objective is to test the non-inferiority of chemotherapy-based conditioning versus TBI-based conditioning regarding 1-year leukemia-free survival (LFS). Secondary endpoints include treatment-related mortality (TRM), cumulative incidence of relapse (CIR), graft-versus-host-disease (GVHD), and overall survival (OS). All patients receive uniform GVHD prophylaxis and post-transplant supportive care.
研究概览
地位
详细说明
Adult ALL patients achieving second complete remission (CR2) represent a high-risk population for relapse after allo-HSCT. Allo-HSCT is the standard curative therapy, yet optimal preparative conditioning remains controversial. Most published evidence focuses on CR1 ALL patients; prospective head-to-head comparison between chemotherapy-only and TBI-based conditioning specifically for adult CR2 ALL is scarce and mainly relies on retrospective cohorts. While TBI-based conditioning provides favorable anti-leukemia effect, it carries substantial acute and late toxicities. Chemotherapy-only conditioning may reduce radiation-related toxicities but raises concern for higher relapse risk. This multicenter randomized phase III non-inferiority trial aims to provide prospective evidence to guide conditioning-regimen selection for adult ALL-CR2 patients undergoing allo-HSCT.
Eligible subjects are randomly assigned 1:1 via central stratified block randomization (variable block sizes:4,6,8). Investigators and participants are not blinded to treatment assignment; outcome assessment and statistical analysis are performed in a blinded fashion.
Experimental Arm (Busulfan-based chemotherapy-only conditioning): Busulfan 0.8 mg/kg q.i.d. day -8 to -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2.
Active Comparator Arm (TBI-based conditioning): Total-body irradiation 770 cGy on day -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2.
Grafts consist of G-CSF-mobilized bone marrow plus peripheral-blood stem cells. Uniform post-transplant GVHD prophylaxis includes cyclosporine-A, mycophenolate mofetil, and short-course methotrexate.
Planned follow-up time-points: +1, +2, +3, +4.5, +6, +9, +12, +18, +24, +36, +48, +60 months post-transplant. Assessments include bone-marrow morphology, multiparameter flow MRD, molecular MRD (fusion gene / Ig-TCR / NGS), chimerism analysis, complete blood count, biochemistry, virology screening, and GVHD evaluation per NIH consensus criteria.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Yu Wang
- 电话号码:8610-8832-6005
- 邮箱:ywyw3172@sina.com
学习地点
-
-
-
Beijing、中国
- Peking University People's Hospital, Beijing Lu Daopei Hematology Hospital, Hebei Yanda Lu Daopei Hospital, Nanfang Hospital, Southern Medical University
-
接触:
- Xiaojun Huang
- 电话号码:8610-8832-6005
- 邮箱:huangxiaojun@bjmu.edu.cn
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 14 and ≤ 65 years (inclusive).
- Diagnosis of acute lymphoblastic leukemia according to NCCN diagnostic criteria.
- Confirmed second complete remission (CR2) before allogeneic hematopoietic stem-cell transplantation.
- Planned to undergo allo-HSCT.
- ECOG performance status < 3.
- Written informed consent obtained.
Exclusion Criteria:
-
Diagnosis of acute biphenotypic leukemia.
-
Uncontrolled active infection at screening.
-
Significant organ dysfunction:
- Liver: ALT/AST > 3.0 × ULN and/or total bilirubin > 1.5 × ULN; severe cirrhosis, portal hypertension or active liver disease.
- Renal: eGFR < 60 mL/min/1.73 m² by CKD-EPI formula or serum creatinine > 1.5 × ULN; regular dialysis requirement.
- Cardiac: NYHA class III-IV heart failure; unstable angina / myocardial infarction / coronary revascularization within prior 6 months; LVEF < 50 %; clinically significant uncontrolled arrhythmia.
- Pulmonary: chronic lung disease requiring long-term oxygen therapy; resting SpO₂ < 92 % (room-air).
-
Participation in another investigational drug trial within past 3 months.
-
Psychiatric disorders interfering with protocol compliance.
-
History of other malignant neoplasms within 2 years prior to screening.
-
Any condition judged by investigator rendering subject unsuitable for trial participation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Chemotherapy-only Conditioning Regimen
intervention: Drug: Busulfan: 0.8 mg/kg intravenous, four times daily, day -8 to day -6 Drug: Cyclophosphamide: 1.8 g/m²/day intravenous, day -5, day -4 Drug: Semustine: 250 mg/m² oral, day -3 Drug: Rabbit anti-thymocyte globulin (ATG): 2.5 mg/kg/day intravenous day -5 to -2 (only for haploidentical transplant recipients) All subjects receive identical post-transplant GVHD-prophylaxis: cyclosporine-A, mycophenolate mofetil, short-course methotrexate; standard supportive care. |
Experimental Arm (Chemotherapy-based conditioning): Busulfan 0.8 mg/kg q.i.d. day -8 to -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2. |
|
有源比较器:TBI-based Conditioning Regimen
intervention Radiation: Total-Body Irradiation (TBI): 770 cGy administered on day -6 Drug: Cyclophosphamide: 1.8 g/m²/day intravenous, day -5, day -4 Drug: Semustine: 250 mg/m² oral, day -3 Drug: Rabbit anti-thymocyte globulin (ATG): 2.5 mg/kg/day intravenous day -5 to -2 (only for haploidentical transplant recipients) All subjects receive identical post-transplant GVHD-prophylaxis: cyclosporine-A, mycophenolate mofetil, short-course methotrexate; standard supportive care. |
Active Comparator Arm (TBI-based conditioning): Total-body irradiation 770 cGy on day -6; cyclophosphamide 1.8 g/m²/day day -5, -4; semustine 250 mg/m² day -3. For haploidentical transplant recipients: rabbit-ATG 2.5 mg/kg/day day -5 to -2. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
1-Year Leukemia-Free Survival (LFS)
大体时间:12 months post-hematopoietic stem-cell infusion]
|
Time from stem-cell infusion to leukemia relapse or death from any cause, whichever occurs first. |
12 months post-hematopoietic stem-cell infusion]
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
1-Year Treatment-Related Mortality (TRM)
大体时间:12 months post-transplantation
|
Cumulative incidence of non-relapse-related death after transplantation (competing risk: leukemia relapse). |
12 months post-transplantation
|
|
Cumulative Incidence of Relapse (CIR)
大体时间:1-year, 2-year, 3-year post-transplantation
|
Cumulative probability of hematologic or molecular leukemia relapse with death as competing risk event. |
1-year, 2-year, 3-year post-transplantation
|
|
Cumulative Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD)
大体时间:Day 100, 1-year, 3-year post-transplantation
|
Cumulative incidence of grade II-IV, grade III-IV acute GVHD (100-day landmark); cumulative incidence of mild/moderate/severe chronic GVHD within 3 years, graded according to NIH GVHD consensus criteria. |
Day 100, 1-year, 3-year post-transplantation
|
|
Overall Survival (OS)
大体时间:1-year, 2-year, 3-year post-transplantation
|
Time from stem-cell infusion until death from any cause. |
1-year, 2-year, 3-year post-transplantation
|
|
Conditioning-related organ toxicities
大体时间:Conditioning start up to post-transplant day +30
|
Incidence of grade 1-4 cardiac, hepatic, renal, gastrointestinal and mucosal toxicities from conditioning initiation up to day +30 post-transplantation, graded by WHO organ-toxicity scale. |
Conditioning start up to post-transplant day +30
|
|
Hematopoietic engraftment
大体时间:Day 30 and Day 90 post-transplantation
|
Neutrophil engraftment: sustained ANC ≥ 0.5 × 10⁹/L for three consecutive days; platelet engraftment: sustained PLT ≥ 20 × 10⁹/L without transfusion support for seven consecutive days. |
Day 30 and Day 90 post-transplantation
|
|
Molecular/Flow-MRD status post-transplant
大体时间:+1, +2, +3, +6, +12 months post-transplantation
|
MRD positive defined as flow cytometry ≥ 0.01 %; or detectable quantifiable fusion-gene / Ig-TCR / NGS clonal signal above assay sensitivity threshold at serial follow-up time-points. |
+1, +2, +3, +6, +12 months post-transplantation
|
合作者和调查者
调查人员
- 首席研究员:Xiao-Jun Huang、Peking University Institute of Hematology
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- ALL-CR2-TBI-Bu
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.